Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Evolus expanded its strategic partnership with Symatese to secure exclusive rights to commercialize the Estyme collection of injectable hyaluronic acid gels in Canada, Australia, and New Zealand. The deal targets a combined annual addressable market of approximately $500 million, with commercialization expected to begin in 2028 subject to regulatory approval.
Key figures
- Tam annual
- $500 million
- Market split neurotoxins
- 60%
- Market split dermal fillers
- 40%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.